Everolimus and Reduced CBD Dosing for TSC Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tuberous sclerosis complex (TSC) are inadequate as they often involve combinations of drugs like mTor inhibitors and antiepileptic drugs, which can have adverse drug-drug interactions, and there is a need for a safer and more effective method to treat seizures and tumors in TSC patients.
Innovation Solution
Administering everolimus in combination with a reduced dose of cannabidiol (CBD), where the CBD dose is decreased by up to 75% compared to standard dosing when co-administered with everolimus, to effectively treat seizures and tumors in TSC patients while minimizing adverse interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard doses of CBD and everolimus are administered together, then treatment coverage for TSC is comprehensive, but adverse drug-drug interactions occur
Solution Approach 1:
The patent applies parameter changes by adjusting the dosage parameters of CBD and everolimus. Specifically, it reduces the CBD dose to at least 10% less than the standard dose when co-administered with everolimus, and adjusts everolimus dosing based on CBD concentration levels. This parameter adjustment resolves the contradiction by maintaining treatment effectiveness while reducing adverse drug-drug interactions.
2Reliability
If multiple antiepileptic drugs are used to treat seizures, then seizure control is achieved, but drug-drug interactions with everolimus increase
Solution Approach 1:
The patent extracts CBD from the broader class of antiepileptic drugs and identifies it as a specific agent that can be safely combined with everolimus. By taking out CBD as a distinct therapeutic option with different interaction characteristics compared to traditional antiepileptic drugs, the patent enables effective seizure control while minimizing harmful drug-drug interactions with everolimus.
3Reliability
If higher doses of CBD are administered, then seizure frequency is reduced, but side effects increase
Solution Approach 1:
The patent applies partial action by administering CBD at reduced doses (at least 10% less than standard) compared to full dosing. This partial administration approach achieves sufficient seizure control without producing excessive side effects, finding the optimal balance point between therapeutic benefit and harmful effects.
Data Source
AI summary
The present disclosure provides methods of treating tuberous sclerosis complex comprising administering cannabidiol and everolimus.